Abstract | The pathogenesis of multiple sclerosis (MS) involves complex interactions between genetic susceptibility and environmental triggers. Clinical observations suggest that the study of sex differences might provide important insight into mechanisms of pathogenesis and progression of the disease in patients. MS occurs more frequently in women than in men, indicating that sex-related factors have an effect on an individual's susceptibility to developing the condition. These factors include hormonal, genetic and environmental influences, as well as gene-environment interactions and epigenetic mechanisms. Interestingly, women do not have a poorer prognosis than men with MS despite a higher incidence of the disease and morerobust immune responses, which suggests a mechanism of resilience. Furthermore, the state of pregnancy has a substantial effect on disease activity, characterized by a reduction in relapse rates during the third trimester but an increased relapse rate in the postpartum period. However, pregnancy has little effect on longterm disability in women with MS. The unravelling of the mechanisms underlying these clinical observations in the laboratory and application of the results to the clinical setting is a unique and potentially fruitful strategy to develop novel therapeutic approaches for MS.
Introduction
Epidemiological studies from the past six decades have shown that women are more likely to develop multiple sclerosis (MS) than are men. 1 Another established clinical phenomenon in MS is the disease-modifying effect of pregnancy, whereby risk of relapse is decreased during the third trimester but increased in the postpartum period. 2 Together, these two clinical observations indicate that the study of sex-related variables might yield substantial insight to better understand the pathological factors involved in MS.
In this Review, we will consider data from clinical studies as well as animal models examining the effects of sex-related factors on MS susceptibility, and on activity and progression in established disease. We also discuss novel therapeutic approaches currently in development that were derived from the study of sex-related factors.
Sex-related differences in MS
Disease susceptibility A distinct female preponderance is observed for a variety of autoimmune diseases. 3 The female to male ratio for MS incidence currently ranges from 2:1 to 3:1 and varies by region. 1 Notably, over the past six decades, this ratio seems to have increased. 1 The difference in the average age of disease onset between male and female patients is small, but there is evidence that in young patients (disease onset before the age of 20 years) the female to male ratio is greater than in the MS population as a whole (3.2:1 versus 2:1, according to one review). 4 A higher incidence of disease in women than in men is apparent across a broad spectrum of autoimmune diseases, including diseases that are driven principally by cell-mediated immune responses (such as MS and rheumatoid arthritis), as well as those with a predominantly antibody-mediated pathogenesis, such as systemic lupus erythematosus (SLE). 3 The factors involved in the increased susceptibility of women to such a wide variety of autoimmune diseases probably reflect a ubiquitous pathway in immune responses.
Certain aspects of sex-related differences in autoimmune diseases can be studied using animal models. For example, in the most widely used animal model of MS, experimental autoimmune encephalomyelitis (EAE), the SJL strain of mice has a female bias for the disease, which is consistent with the female preponderance in MS. 5 Similarly, an increased female susceptibility is seen in animal models of other autoimmune diseases, including diabetes mellitus, thyroiditis, rheumatoid arthritis and SLE. 3 However, some strains of mice, such as B10. PL and PL/J, demonstrate more-severe EAE in males than in females, 6 and no difference in disease incidence is seen between the male and female mice of the C57BL/6 strain. 7 As such, sex-specific factors seem to interact with the autosomal genetic background, which supports evidence linking autosomal genes with an increased risk of developing MS in one sex but not the other.
Disease activity and progression
Early predictors of future disability in the major subtypes of MS (relapsing-remitting MS and secondary progressive MS) include sex, age of disease onset, and degree of recovery from the first episode. 9, 10 In addition, higher levels of inflammatory lesions, as measured by gadolinium enhancement on brain MRI, have been shown in female than in male patients with MS. 11, 12 However, large studies that controlled for age at disease onset and type of MS did not find a difference in levels of inflammatory lesions between the sexes. [13] [14] [15] Nevertheless, the two sexes exhibit clear differences in immune responses. Responses to various immune challenges are greater in women than in men, 16 as observed when comparing autoantigen-specific responses in female and male patients with MS. [17] [18] [19] Specifically, when peripheral blood mononuclear cells from female and male patients with MS were stimulated with proteolipid protein, myelin basic protein or myelin oligodendrocyte glycoprotein, women demonstrated increased IFN-γ secretion and reduced IL-5 secretion compared with men. 18, 19 These findings support a link between a polymorphism of the gene encoding IFN-γ and reduced MS susceptibility in men but not in women. 17 A large study of the natural history of MS, which included 1,844 patients with relapsing-remitting, secon dary progressive or primary progressive types, demonstrated that the median time between disease onset and reaching a given disability level was shorter in men. 9 A subsequent review of findings from a large, multicentre, placebo-controlled trial demonstrated that while there was no apparent effect of sex-related factors on short-term disability related to relapses in patients with re lapsing-remitting MS, an increased rate of progression of long-term disability was observed in men with primary progressive MS. 20 Furthermore, another natural history study, which included a large number of patients with MS who had not received treatment during the study, found that the male sex was associated with a shorter time to and a younger age for conversion to secon dary progressive MS. 21 Grey matter atrophy has also been found to be greater in men than in women with MS. 13 In addition, male patients with MS might have a higher proportion of lesions evolving into black holes Key points ■ Women are at increased risk of developing multiple sclerosis (MS) but have a reduced relapse rate during pregnancy, indicating that sex-related factors are important in disease pathogenesis and activity ■ While women have a higher incidence of MS and a more robust immune response, male patients can demonstrate a more progressive disease course ■ The effects of sex-related factors on disease relapse should be considered separately from the effects on disease progression ■ Sex hormones and sex chromosomes can independently contribute to disease incidence and progression ■ Sex-related factors might exert different, even opposing, effects on the peripheral immune system and the CNS ■ The increasing difference in MS incidence between men and women is likely to be attributable to the interaction of sex-specific factors with autosomal genes, environmental factors and/or behavioural factors (indicative of destructive lesions) on MRI than female patients; 11 however, this finding has not been replicated in further studies. 13 To summarize, findings on the activity and progression of MS in male and female patients have produced something of a conundrum. In women, the incidence of MS is higher and peripheral immune responses are more robust. However, contrary to expectations, dis ease progression and neurodegeneration are either faster in men or are, at best, no different between the sexes. Consequently, the study of sex-related factors in MS needs to consider the possibility that these factors might have different and possibly opposing roles in the immune system and the CNS.
Mechanisms for sex-related differences Hormones The female bias for MS could theoretically be a result of either the deleterious effect of female sex hormones or the protective effect of male sex hormones. There are no convincing data that low levels of cyclical ovarian hormones in female mice are disease promoting in EAE. Results from studies have been conflicting; some research shows no effect of ovariectomy, 22 while other research demonstrates a slight worsening of clinical EAE in mice following ovariectomy compared with a sham-operated group, 23, 24 suggesting that a slight protective effect is conferred by low levels of female hormones. By contrast, physiological levels of testosterone are clearly protective in EAE, since castration of young male mice has been shown to worsen disease course. 25 Several immuno modulatory, and possibly neuro protective, mechanisms of testosterone have been described; 25 notably, gonadectomy (to remove endogenous testo sterone) increased disease susceptibility in strains of mice characterized by a female sex bias for EAE. 26 This finding suggests that a protective effect of physiological testosterone might be responsible, at least in part, for the decreased male susceptibility to disease in a given genetic background.
Genetic factors
Differences between the sexes in EAE and MS might be influenced by genetic factors. Novel mouse models that allow independent investigation of the effects of sex hor mones and chromosomes have provided interesting results. In these mice, the testis-determining gene, Sry, is deleted from the Y chromosome and inserted as a transgene on an autosome, thereby enabling a distinction to be made between genetic and hormonal sex. The XX sex chromosome complement was associated with more-severe disease compared with the XY -complement in both EAE and pristane-induced lupus, demonstrating the importance of genetic sex. 27 Sex chromosomes have also been shown to affect autoantigen-specific immune responses. 27, 28 Findings from further studies have suggested that the Y chromosome contains polymorphic genes that might reduce susceptibility for developing EAE. 29, 30 The effects of sex chromosomes in EAE might, therefore, be due to a protective effect conferred by genes unique to the Y chromosome in male mice or a disease-promoting effect conferred by a gene on the X chromosome in female mice (since some genes escape X-inactivation, resulting in double dosage in female [XX] mice). Finally, since the male X chromosome genes are always inherited from the mother, whereas the female X chromosome genes can be inherited from either the mother or the father, differential imprinting of genes on the X chromosome could also underlie sex-chromosome-related differences in disease.
Epigenetics and gene-environment interaction
The transfer of MS risk demonstrates a maternal p arentof-origin effect 31 that is related to HLA background. 32 Parent-of-origin effects are generally considered to reflect genomic imprinting-an epigenetic mechanism that involves methylation and histone modification to achieve monoallelic gene expression. A parent-of-origin effect has been described in imprinting of both sex chromo somes and autosomal genes, 33 providing evi dence that environmental factors can influence imprint ing in a sexually dimorphic manner. 34 How ever, parent-oforigin effects can also be caused by other mecha nisms; environ mental factors, such as sunlight, can affect functional levels of vitamin D, which in turn alter its interaction with genes that confer susceptibility to MS. 35, 36 Furthermore, the female to male ratio for MS susceptibility is higher in patients with HLA-DRB1*15-positive genotypes than in patients with HLA-DRB1*15-negative genotypes, sug gesting a role for the HLA in the observed gender bias via gene-environment interaction and e pigenetic mechanisms. 37 Interestingly, the female to male ratio for MS incidence has increased in the past six decades in most study locations. 1 The increase in this ratio is attributable to an increased incidence of MS in women rather than a decreased incidence in men. The reasons for this phenomenon remain speculative, although the time span over which this change is occurring probably excludes a genetic cause. 38 Instead, the underlying factors might be environmental or related to gene-environment interactions. To explain the change in sex ratio, proposed environmental factors would have to either interact with factors that are sexually dimorphic, or be more commonly encountered in one sex than the other. For example, while changes in the female to male ratio seem to predate the use of oral contraceptives or changes in smoking behaviour in women, other factors such as changes in lifestyle, roles in the workforce, dietary habits or alterations in menarche could contribute to the increasing incidence of MS in women. 38 To date, however, little direct evidence has been found for any of these factors. Experimental data in mice suggest that the peroxisome proliferator-activated receptor α, which is involved in differences in lipid metabolism between the sexes, also exerts sex-specific effects in EAE, indicating a potential interaction between sex-related factors and diet in autoimmunity. 39 In women with MS, increased parity has been associated with a decreased risk of a first demyelinat ing event (Table 1) . 40 In this study, the researchers noted an association between the increased incidence of MS in women over the past six decades and the number of women waiting longer to have children and having fewer children over this same time period. As such, the increasing incidence of MS in women might, in part, be due to a loss of or delay in the protection conferred by being multiparous.
Testosterone therapy
As already discussed, removal of endogenous testosterone affects disease susceptibility in strains of mice that exhibit a sex bias in EAE. However, supplemental testo sterone treatment was shown to be protective in gona dally intact male mice with EAE in strains both with and without a sex bias for the condition (the SJL and C57BL/6 strains, respectively). 26 This result suggests that mechanisms for dis ease protection conferred by endogenous testosterone and the mechanisms underlying exogenous testosterone treatment might differ. Importantly, a thera peutic effect in EAE can also be seen when dihydrotestosterone is used, indicating that androgens are not protective merely via conversion to oestrogen. 26 A pilot clinical trial of testosterone treatment was conducted in men with relapsing-remitting MS. 41 While no effect was found on active lesions (possibly owing to low levels of inflammatory activity at baseline), the annualized brain atrophy rate seen on MRI scans was reduced during the treatment phase compared with the pretreatment period. One of several potential mechanisms through which testosterone could exert a protective effect is the induction of neurotrophic factors in peripheral blood mononuclear cells. 42 Large placebo-controlled trials of testosterone treatment in men with MS are needed.
Pregnancy and MS
Disease susceptibility MS onset is rare during the latter half of pregnancy, but the risk of developing MS is elevated in the postpartum period. 43 Several epidemiological studies have found no associations between the number of pregnancies and subsequent MS risk. [43] [44] [45] [46] [47] However, one study has demon strated a reduced risk (by approximately 50%) of a first clinical presentation for a demyelinating event for every birth, so that in women who had experienced three or more pregnancies, the risk of MS was further reduced to one-quarter, and in those who had experienced five or more pregnancies, the risk was reduced to one-twentieth. 40 This effect was independent of other established risk factors, such as HLA and the Epstein-Barr virus. Moreover, this association was seen in women with MS who have children but not in men with MS who have children, indicating that prenatal factors in the mother, rather than postnatal factors in the family environ ment, were underlying the parity effect. Importantly, the end point in this study was a first demyelinating event, and not relapses in established MS, thereby eliminating any selection bias resulting from the increased likelihood of those with mild disease activity to become pregnant compared with indivi duals with moresevere disease. Further examination of the effect of parity on MS risk is warranted (Table 1) .
Disease activity and progression
The effects of pregnancy on disease activity in MS and other autoimmune diseases are well-known and established in the literature. 3 Research involving patients with MS has demonstrated a decrease in relapse rates by approximately 70% in the third trimester compared with pre-pregnancy rates, 2,48-51 and has consistently shown an increase in the relapse rate during the first 6 months postpartum. 52 The reduction in relapse rates during pregnancy is remarkable considering that the reduction induced by current MS treatments ranges from 30-60%. 53 The reduction in disease activity during pregnancy is a seminal clinical observation that needs to be understood and translated for therapeutic benefit ( Table 1) .
The effects of pregnancy on the level of permanent disability remain unknown. Findings from short-term 2, 54 and long-term 44, 55 studies in patients with MS have not demonstrated any effect of pregnancy on the level of subsequent permanent disability sustained by the patient. However, other long-term studies investigating the time taken to reach a given level of disability, some of which included groups of patients that were initially matched for deficit, disease duration and patient age, have produced results that suggest a protective effect of pregnancy on disability. [56] [57] [58] [59] These observational studies are prone to selection bias, since rigorous matching of groups at baseline is not always possible. For example, as previously discussed, women with clinically benign disease (low inflammatory activity and reduced disability progression) are potentially more likely to opt to have children than are those with more severe disease. Overall, the available data do not provide convincing evidence for a substantial beneficial effect of pregnancy on long-term disability (Table 1) .
Protective mechanisms during pregnancy
Pregnancy is not protective in all autoimmune diseases; for example, it is protective in MS, rheumatoid arthritis and psoriasis, but not in other diseases such as SLE. 60 This observation would suggest that alterations in the immune system that occur during pregnancy are generally not immunosuppressive-rather, they shift immune responses in a way that is beneficial in diseases primarily driven by cell-mediated immunity (such as MS) but is not beneficial in primarily antibody-mediated diseases (such as SLE). Insights into the immunopathogenesis of MS relapses can be gained by examining current concepts in reproductive immunology (Box 1).
Change in immune function
Studies conducted in small numbers of patients with MS have investigated immune changes that occur during pregnancy. A genome-wide analysis has provided evidence for a decrease in transcription of several in flammation-related genes in peripheral blood mononuclear cells during pregnancy, with a corresponding increase in the transcription of these genes postpartum. 61 A shift from T helper (T H )-1 to T H 2 cells was shown on analysis of both mRNA and protein in the peripheral blood of patients with MS who were followed longitudinally during pregnancy. 48, [62] [63] [64] A decline in the frequency of IFN-γ producing CD4 + T cells during pregnancy has been demonstrated in one study of patients with MS, but no increase in this cell population was found postpartum. 65 Levels of serum IL-8 have also been shown to decrease during pregnancy in patients with MS. 66 Other studies in this patient group have produced conflicting results, demonstrating either an increase in T-regulatory (T REG ) cells 67 or a decrease in this cell population, 68 and no change in T H 17 cells. 68 However, a study conducted in Finland with a larger number of participants did not find any effect of pregnancy on the numbers of T REG cells in patients with MS. Nevertheless, the researchers did note an increase in CD56 bright natural killer cells during pregnan cy, and a decrease in these cells postpartum. 48 
Endocrine factors
As already discussed, the relapse rate in pregnant patients with MS is substantially reduced during the third trimester. 2 The levels of two oestrogens (oestradiol and
Box 1 | Pregnancy and autoimmunity-insights from reproductive immunology
During pregnancy, a balance in the immune system has to be achieved to ensure survival of the fetus and the mother. 120 The classic concept of the fetus as a semi-allograft whereby paternal alloantigens evade detection by the maternal immune system has been modified. Researchers have shown that the maternal immune system recognizes paternal antigens but temporarily inhibits the immune response. 121 Pregnancy is, therefore, an immunomodulatory state characterized by a complex network of recognition and communication. 122 Numerous studies have demonstrated a T-helper (T H )-1 to T H 2 cell shift during pregnancy, which could contribute to the beneficial effects of pregnancy in cellmediated autoimmune disorders, such as multiple sclerosis (MS) and rheumatoid arthritis. However, animal models suggest that T H 2 cytokines are not essential for fetal survival. 123 The notion that pregnancy represents a T H 2 shift 124 might, therefore, be overly simplistic. 125 Mechanisms of immune tolerance during pregnancy have mainly been investigated at the maternal-fetal interface. 126 In the context of the beneficial effects of pregnancy on cell-mediated autoimmune diseases, however, the more-subtle shifts within systemic immune responses of the mother 127 might be important. For example, numbers of T-regulatory (T REG ) cells increase in the maternal circulation early during pregnancy in both mice 128 and humans 129 without MS. In addition, an increase in the ratio between T REG cells and T H 17 cells has been described, 130 which might have a role in autoimmune inflammation. 131 Experimental data suggest that transfer of T REG cells from pregnant mice is sufficient to confer protection from autoimmunity in nonpregnant mice. 119 This mechanism might be antigen-specific, since T REG cells from pregnant mice that had not been exposed to the autoantigen could not confer protection. 119 However, the cellular and molecular mechanisms of this phenomenon remain to be elucidated.
o estriol) and progesterone increase progressively during pregnancy, and peak in the third trimester. 69 Within days after the birth, levels of these hormones fall, making their temporal profile consistent with the protection conferred by pregnancy on the MS relapse rate. 70 Both oestriol and oestra diol treatment can ameliorate EAE. 25 By contrast, treatment with progesterone demonstrates only small effects on EAE when used alone, 71, 72 and the results from one study involving Lewis rats suggested that pro gester -one treatment might even be deleterious in EAE. 73 With combination therapy, however, pro gesterone seems to add to the protective effects of oestrogen treatment. 74 The complementary effects of oestrogen and pro gesterone might be attributable to beneficial effects of progesterone on the axon; namely, decreased de myelination or increased remyelination. 75, 76 The roles of individual hormones are not mutually exclusive. 1,25-dihydroxy vitamin D is increased during pregnancy. In EAE, diets high in vitamin D reduced disease severity in female but not male mice, 77 and the protective effect of 1,25-dihydroxyvitamin D in EAE was subsequently shown to depend on the presence of oestrogen. 78 Intriguingly, one epidemiological study provided indirect evidence that vitamin D intake during pregnancy in healthy women could also decrease the risk of MS in the offspring. 79 Levels of serum cortisol (a potent immunomodula tory steroid) also increase to within the high end of the normal range during late stages of pregnancy. 69 Raised levels of 11β-hydroxysteroid dehydrogenase 1 and increased gluco corticoid receptor α expression have been described in decidual cells during the second trimester of human pregnancy, 80 potentially increasing cortisol bioavailability even before the increase in circulating cortisol levels that occurs in the third trimester.
Prolactin levels are increased during pregnancy and remain elevated during the postpartum period in individuals who are breastfeeding. Interestingly, pro lactin regulates oligodendrocyte precursor proliferation. 81 The state of pregnancy in mice increases the capacity to remyelinate noninflammatory white matter lesions-an effect that can be mimicked by prolactin. 81 However, prolactin could also be detrimental since it is thought to be immunostimulatory; indeed, blocking of prolactin with bromocriptine treatment was shown to ameliorate EAE. 82 Findings from studies in humans involving small study populations have suggested that hyper prolactinaemia might be associated with MS relapses. 83, 84 Any given factor in pregnancy might, therefore, have different and even opposing effects in the immune system compared with the CNS-an important consideration when ex ploring therapeutic options in MS.
Breastfeeding and disease relapse
Research has shown no effects of breastfeeding on the postpartum relapse rate in patients with MS. 54, [85] [86] [87] Instead, the relapse rate before pregnancy was found to be the best predictor of postpartum relapse rate. 2, 54, 87 However, results from other studies suggest that exclusive breastfeeding might be associated with a lower relapse rate than no breastfeeding or partial breast feeding. 88, 89 Of note, classification bias rather than causality could underlie this finding, since individuals who had a relapse while breastfeeding could have stopped breastfeeding to take disease-modifying drugs. 88 Furthermore, mothers with active disease prior to pregnancy are less likely to breastfeed, 54, 86 which raises the issue of selection bias. No convincing evidence that breastfeeding causes a reduction in MS relapses is available as yet.
Microchimerism
Some researchers have suggested that microchimerism, the exchange of haematopoietic stem cells between the mother and fetus during pregnancy, might have a role in autoimmunity. 90 However, existing data on parity and MS incidence-which show either a decrease or no alteration in risk of MS with increasing parity-do not support a major immunopathogenic role for micro chimerism in MS. [43] [44] [45] [46] [47] In addition, an association between microchimerism and MS should produce different levels of risk in women who have children from several different partners and, to our knowledge, no evidence for such an association has been found. 91 Oestrogen therapy EAE in guinea pigs, rats, rabbits and mice improves during pregnancy, 22, 92, 93 mirroring the effects seen in MS. Studies in EAE support the therapeutic potential of oestro gens via numerous anti-inflammatory effects in the peripheral immune system, including cytokine shifts, downregulation of chemokines in the CNS, modula tion of dendritic cell function, increased numbers of T REG cells, and decreased expression of matrix metallo proteinases. 94 Importantly, in EAE oestriol is protective at doses that are similar to physiological levels in murine pregnancy, 23, 71 while oestradiol requires supra physiological doses to achieve the same effects. 23 Oestrogens are lipophilic and can cross the bloodbrain barrier, and thus also have the potential to directly affect CNS cell populations. 95 Two main oestrogen receptor (ER) subtypes-the nuclear receptors ERα and ERβ
96
-are known to exist, but oestrogens also have nongenomic membrane effects. 97 The integral membrane protein G-protein-coupled receptor (GPR30), which has a high affinity for oestrogen, might mediate some of the therapeutic effects of this hormone in EAE. [98] [99] [100] The protective effect of oestrogen treatment (with oestradiol and oestriol) in EAE was shown to depend on the presence of ERα but not ERβ, 101, 102 and stimulation of ERα was sufficient for protection to be conferred in EAE. 103, 104 Importantly, expression of ERα in the peripheral immune system was dispensable for the therapeutic effect; 105 therefore, increasing attention has been given to the CNS targets of oestrogens. Within the CNS, ERα expression by astrocytes (but not by neurons) was required for the therapeutic (neuroprotective and anti-inflammatory) effects of a synthetic ERα ligand in EAE. 106 ERβ ligand treatment does not have potent effects on the peripheral immune system or on the level of CNS infiltration during EAE, 107 but treatment can qualitatively affect the composition of the CNS infiltrate by reducing dendritic cells therein. 108 ERβ ligand treatment also confers some clinical protection late in the course of EAE, including reduced demyelination, 107 preserved axon numbers, 109, 110 and increased functional remyelination. 111 Findings from animal models also suggest that ERβ signalling in microglia can exert protective effects in CNS inflammation by repressing transcription of inflammatory genes without the binding of ERβ to its target DNA sequence. 112 Of potential therapeutic interest, this mechanism is activated by endogenous nonoestrogenic steroids such as 5-androsten-3β, 17β-diol. Advances in the understanding of molecular mechanisms involving CNS oestrogen receptor signalling in neuroinflammation could lead to specific targeting of pathological processes-particularly those involving glial cells-using novel ER ligands.
Few studies have investigated the therapeutic or preventative effects of oestrogen administration in MS. Results from four epidemiological studies of oral contraceptive use 43, [45] [46] [47] found no evidence to suggest an important role for oral contraceptive use in MS susceptibility. A small pilot study involved administration of oestriol at doses to induce pregnancy levels of the hormone in the serum of female patients with MS who were not pregnant. 113 Results from this trial have demonstrated a favourable shift in the cytokine profile, decreased release of matrix metalloproteinase-9 by peripheral mononuclear blood cells, 114, 115 and a reduction in gadoliniumenhancing lesions on MRI. 113 Large placebo-controlled clinical trials of oestrogen therapy in MS are ongoing, including a multicentre trial of oestriol therapy in combination with glatiramer acetate, 116 and a trial examining the effects of oestradiol and progestin treatment in preventing postpartum relapses of MS.
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Future research
The goal of sex differences research is not merely to discern why women are at increased risk of MS, but also to examine the reasons why most men have a decreased risk. Pregnancy is a state that is clearly protective with regard to relapses in patients with MS, although there is no conclusive evidence that pregnancy affects long-term dis ability. The effects of pregnancy on the immune system have been investigated, but studies addressing the effects of pregnancy on the CNS (that are not confounded by differences in the immune system) are needed ( Table 2) .
Determination of the cellular and molecular mechanisms that mediate protection during late pregnancy would reveal important targets for new drug development in both women and men. Although evidence exists for changes in the expression of certain immune markers in patients with MS during pregnancy, no marker has, as yet, been convincingly associated with the decrease in relapse rates observed during the third trimester. To better understand the effects of pregnancy on MS, we must move beyond cytokine shifts and enumerative changes in cell phenotype, and future studies should include functional analyses of, for example, T REG cells and CD56 bright natural killer cells. In addition, little evidence is available regarding T H 17 cells, and the potential contributions of the innate immune system in pregnancy have yet to be explored. Importantly, data regarding the immunological correlates of postpartum relapses are still missing, and this is, therefore, an important avenue for further research. Experimental evidence from an arthritis model 119 indicates that some of the immune shifts that occur during pregnancy might be autoantigen-specific, which should also be taken into consideration in future studies. Further insight into the effects of hormones on the immune system versus the CNS is also needed to Determine whether the postpartum period has an effect on disability
Future studies should aim to identify the underlying aetiological processes involved in MS susceptibility, activity and progression so that novel treatments can be developed to target these factors. Abbreviation: MS, multiple sclerosis.
effectively target therapeutic strategies in an effort to either mimic the protective aspects of pregnancy or prevent the detrimental effects of the postpartum period.
Conclusions
The study of sex differences is important for both women and men with MS. The female sex confers an increased susceptibility for developing MS; however, it does not cause a more aggressive disease course or a poorer prognosis in this sex compared with men despite a higher incidence and more-robust immune responses. If the CNS in women is more resistant to neurodegeneration than in men, then the mechanisms of this sex-related difference could be exploited to develop neuroprotective therapies. In addition, the observed increase in the sex ratio for MS incidence over the past few decades suggests that disease susceptibility is influenced by sex-specific associations with environmental factors or by gene-environment interactions. Some of the underlying factors might be of a behavioural nature, and a better understanding of these associations could potentially be relevant to disease prevention in some patients. Both a substantial decrease in MS relapses during pregnancy and a rebound increase in relapse risk postpartum are well-established in the literature. However, the biological effects that underlie this phenomenon are poorly understood. Future studies in this area could help to develop approaches that not only prevent postpartum relapses in female patients, but also lead to novel disease-modifying therapies that are be neficial in both men and women with MS.
Review criteria
PubMed was searched for English-language articles published from 1975 to December 2011 using the search terms "gender or sex", "multiple sclerosis", "male", "female", "estrogen or testosterone", "hormones", "pregnancy", "sex chromosome", "environment", "MRI" and "immune". The reference lists of identified articles and the authors' own files were also searched for further relevant papers.
